Physician profile
Kirk D Ridley
NPI 1922093954
$17,677.39
in general payments reported to CMS, 2019-2025
63 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,122 · 2020: $1,393 · 2021: $2,970 · 2022: $3,218 · 2023: $3,068 · 2024: $2,736 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,974.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,644.33 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $2,357.35 | 2019-2025 | |
| Lilly USA, LLC | $1,318.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $1,280.86 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Pfizer INC. | $1,135.79 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $928.97 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $895.71 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $871.83 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $716.34 | 2019-2024 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $484.48 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $451.07 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $407.63 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $352.69 | 2019-2024 | Belsomra, Capvaxive, Steglatro |
| Otsuka America Pharmaceutical, INC. | $316.24 | 2019-2025 | Rexulti |
| Allergan, INC. | $244.22 | 2019-2020 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Ridley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.